Table 1 The clinical and histopathological characteristics of the included patients

Enrolled patients

313

190

123

Tumor size (mean), cm

2.17

2.03

2.40

  <2

170

121(63.7%)

49(39.8%)

<0.001

  2-5

138

65(34.2%)

73(59.3%)

  ≥5

5

4(2.1%)

1(0.8%)

Nodal status

  0

206

130(68.4%)

76(61.8%)

0.310

  1-3

81

44(23.2%)

37(30.1%)

  4-9

14

7(3.7%)

7(5.7%)

  ≥10

12

9(4.7%)

3(2.4%)

Nuclear grade

<0.001

  Grade 1 or 2

127

109(57.4%)

18(14.6%)

  Grade 3

175

76(40.0%)

99(80.5%)

  Unknown

11

5(2.6%)

6(4.9%)

Histologic grade

<0.001

  Grade 1 or 2

131

113(59.5%)

18(14.6%)

  Grade 3

153

59(31.0%)

94(76.4%)

  Unknown

29

18(9.5%)

11(9.0%)

PR status

<0.001

  Positive

133

128(67.4%)

5(4.1%)

  Negative

180

62(32.6%)

118(95.9%)

HER2/neu status

<0.001

  Positive

45

9(4.7%)

36(29.3%)

  Negative

246

170(89.5%)

76(61.8%)

  Unknown

22

11(5.8%)

11(8.9%)

Operation

0.014

  Conservation

175

117(61.6%)

58(47.2%)

  Mastectomy

138

73(38.4%)

65(52.8%)

Adjuvant chemotherapy

<0.001

  No

131

103(54.2%)

28(22.8%)

  Yes

182

87(45.8%)

95(77.2%)

Adjuvant Radiotherapy

0.129

  No

133

74(38.9%)

59(48.0%)

  Yes

180

116(61.1%)

64(52.0%)

Adjuvant hormonal therapy

  No

3(1.6%)

  SERM

36(18.9%)

  AI

137(72.1%)

  Switch*

14(7.4%)

Distant metastasis

7(3.7%)

15(12.2%)

0.006